Brind.

CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents.

1 report, 1 independent Updated Aug 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

CureVac Pfizer

How it developed

Newest first. Tap a step to see who reported it.

Jun 7GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.Sub-event
Aug 15CureVac and Pfizer are collaborating on mRNA vaccine patents, leading to EMA clearance for CVHNLC.1 source
- ACCESS Newswire

Keep exploring

The entities involved

CureVac
biopharmaceutical company in Germany

Nothing else this week.
Pfizer
American multinational pharmaceutical and biotechnology corporation
- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22

Coverage

Newest first; wire copies grouped

Aug 15ACCESS NewswireCureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and P